GLP-1s are everywhere right now—and for employers, they’re creating one of the biggest pharmacy questions of the moment: Do we cover them? Limit them? Or rethink our approach entirely? 

There’s no easy answer. GLP-1s are clinically effective, in high demand, and expanding into new use cases. But they’re also expensive and growing quickly—especially when used for weight loss. 

So, the real challenge is how to manage them in a way that balances cost, access, and long-term sustainability. 

GLP-1 demand is accelerating—and not just for diabetes. 

New indications, increased awareness, and strong outcomes are driving more interest, especially around weight loss. At the same time, these medications come with: 

Put those together, and it’s easy to see why this has become a major pressure point for employers.  

There’s a real push-and-pull happening with GLP-1s. Expanding access can support employee health and engagement but can also lead to rapid cost growth and unpredictability. 

That’s why most organizations aren’t asking if they should address GLP-1s—they’re trying to figure out how. 

And for most, it comes down to three paths: 

The path that’s right for your organization depends on which outcomes you prioritize. 

Treating GLP-1s as a simple “cover or don’t cover” decision oversimplifies the challenge. They require ongoing strategy. 

What we’re seeing across the market is that the most effective approaches tend to include a mix of: 

Because what works today may need to change as the market shifts. 

Another layer of complexity: GLP-1 access isn’t limited to the traditional pharmacy benefit anymore. Employers are increasingly exploring options like: 

These approaches can create new opportunities—but they also come with tradeoffs, particularly around: 

That makes alignment even more important. 

Organizations navigating the GLP-1 challenge well tend to have a few things in common. 

They’re not reacting. They’re being intentional. 

And most importantly, they treat GLP-1s as an ongoing strategy—not a one-time decision. 

Broader data and perspective can help guide and refine your strategy. Looking across multiple populations can provide a clearer view into: 

That kind of insight helps organizations make more informed decisions—and adjust faster when needed. 

GLP-1s are reshaping pharmacy strategy—and they’re not going away. Smart organizations will approach them in a way that balances access, cost, and long-term sustainability.